Official Title
COVID-19 Infection at Samusocial in Paris: Descriptive and Serological Survey
Brief Summary

Study of COVID-19 seroprevalence in precarious population living in shelters of Samusocial de Paris and in staff working in these centers during COVID-19 epidemic.

Detailed Description

After emergence of a new coronavirus (Severe Acute Respiratory Syndrome Coronavirus 2,
SARS-CoV2) responsible for a cluster of respiratory infection at Wuhan, China, on January,
7th 2020, first cases were diagnosed in France in January 24th 2020.

Health care components of Samusocial de Paris (Lits Haltes Soins Santé (LHSS)) were created
in 2006. They provide medical care for homeless people and people in social distress not
needing an hospitalization. Sometimes there are 3 persons in a bedroom.

In december 2018, a special shelter for isolated women or women in precarious situations
opened.

Because of the living conditions in these centers and the difficulty for these populations to
respect social distancing and hygiene recommendations.

A first case of COVID-19 was identified on March 8th 2020 in one of these healthcare centers.
Other cases were detected in the same center, then in another center on March 16th, then in
the dormitory of the women shelter on March 30th.

A recent study showed an important prevalence of SARS-COV2 in residents of a homeless shelter
in Boston (36%), most of them were asymptomatic.

Seroprevalence studies are done in general population or in health care workers, but don't
include vulnerable people.

It seemed important to us to describe the epidemic in these centers and to study COVID-19
seroprevalence in these particular populations.

Completed
SARS-CoV2 Infection

Diagnostic Test: blood test for SARS-COV2 serology

each person who will accept to participate will have a bood test for a SARS-COV2 serology

Eligibility Criteria

Inclusion Criteria:

- to have been hosted or working in one the three centers (LHSS Ridder-Plaisance or
Saint Michel or Halte femmes) between march and may 2020

- to be aged 18 y or more

- to be able to give an informed consent

Exclusion Criteria:

- people who refuse to participate

- not being able to give an informed consent

- Person subject to a legal protection measure (safeguard of justice, curatorship or
guardianship)

- Person who does not understand the information provided on how to carry out the
research

- Obstacle to venous sampling

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
France
Locations

Haltes pour femmes
Paris, France

LHSS Saint-Michel
Paris, France

LHSS Ridder-Plaisance
Paris, France

Yazdan Yazdanpanah, MD PHD, Principal Investigator
Assistance Publique - Hôpitaux de Paris

Institut National de la Santé Et de la Recherche Médicale, France
NCT Number
Keywords
seroprevalence
SARS-CoV2
Precarious
MeSH Terms
Infections
Communicable Diseases
COVID-19